AstraZeneca PLC (ZEG.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
As of 09:57AM CEST. Market open.
| Previous Close | 143.00 |
| Open | 143.55 |
| Bid | 142.10 x 30000 |
| Ask | 142.20 x 30000 |
| Day's Range | 142.10 - 143.55 |
| 52 Week Range | 112.35 - 150.60 |
| Volume | |
| Avg. Volume | 33,012 |
| Market Cap | 220.371B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 37.61 |
| EPS (TTM) | 3.78 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 2.65 (1.85%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
ZacksAstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
ReutersAstraZeneca's COVID prevention drug application gets EU fast-track assessment
"The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said. An accelerated assessment aims to speed up the EMA's review of a market authorisation application. AstraZeneca acquired sipavibart from RQ Bio in May 2022.
ZacksWhy Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
© 2024 Yahoo. All rights reserved.